Baird Research Park
1576 Sweet Home Road
Amherst, NY 14228
Toll Free: 866-894-8887
716-688-4790
Fax: 716-688-5811
Email: tech@ort-inc.com
August 2nd 2005
Oncology Research Therapeutics announces that it has received full Medicare approval for reimbursement of it's chemo-resistance based assays. "This is a pivitol step in launching our medical laboratory services to Oncologist and will help to further our mission to improve clinical outcomes for cancer patients. Cancer based diagnostics will play an ever important role managing the costs of this devastating disease by making better drug choices". reports John Moran Jr., Oncology Research Therapeutics.
Oncology Research Therapeutics announces that it has received full Medicare approval for reimbursement of it's chemo-resistance based assays. "This is a pivitol step in launching our medical laboratory services to Oncologist and will help to further our mission to improve clinical outcomes for cancer patients. Cancer based diagnostics will play an ever important role managing the costs of this devastating disease by making better drug choices". reports John Moran Jr., Oncology Research Therapeutics.
May 31st 2005
Oncology Research Therapeutics receives a provisional CLIA certification from the State of New York. The license allows ORT to perform specialized services as a clinical Oncology and Immunology Laboratory.This pivitol step will allow ORT to conduct its chemo-resistance and sensitivity assays and allow ORT to receive insurance reimbursement.
